The BioLymph study – implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

Click to increase image sizeClick to decrease image size

Acknowledgements

We are deeply indebted to the clinical research personnel at the departments of Hematology, Pathology, and Clinical Genetics for their work with patient inclusion and collection of materials in the present study, in particular Emilie Nelson, Anna-Lena Fridolfsson, Shaila Petersson, Lylie Mbuyi, Harriet Ryblom, and Hero Nikdin. We further acknowledge the excellent support by Clinical Genomics Stockholm at SciLifeLab in the NGS-related work of the study. Funding support is provided by Theme Cancer, Karolinska University Hospital (first 100 patients), Region Stockholm (No. 20190494, 500306 and FoUI-961732), King V Jubilee Fund (No. 214153), Medical Diagnostics Karolinska (No. 2022-3763), the Swedish Childhood Cancer Fund (No. TJ2021-0125, KP2021-0017) and through Genome Medicine Sweden (GMS). GMS is funded by the Swedish Innovation Agency Vinnova and through collaborating partners.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Study data are available upon request if in line with ethical and legal permissions.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This work was supported by Barncancerfonden; Radiumhemmets Forskningsfonder; Stockholms Läns Landsting.